Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events

Recruiting

I'm Interested

Trial ID: NCT05224661

Age - 18 Years-N/A Condition - Leukemia, Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML) Gender - All Accepting Healthy Volunteers - No

Purpose

Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT).

Official Title

Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events

Stanford Investigator(s)

Lori Muffly
Lori Muffly

Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Eligibility


Inclusion Criteria:

   1. Provision of signed and dated informed consent form

   2. Stated willingness to comply with all study procedures and availability for the
   duration of the study

   3. Aged at least 18 years old at time of consent

   4. Diagnosed with AML, in complete remission

      1. Complete remission (CR) definition per local institutional criteria

      2. CR with incomplete hematologic recovery (CRi) is not an exclusion criterion

      3. MRD positivity is not an exclusion criterion

   5. Undergoing alloHCT

   6. Has specimen from time of AML diagnosis available

Exclusion Criteria:

   1. Diagnosis of acute promyelocytic leukemia

   2. Prior alloHCT

View More
View Less

Intervention(s):

other: Prospective determination of the clinical utility of measurable residual disease (MRD) testing

Recruiting

I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Audrey Xu
650-725-1647

New Trial Alerts

Receive email alerts when trials open to patients.

©2022 Stanford Medicine